Such EGFR-bypass signalling mechanisms have been linked to drug resistance in cancer cells in the past [65,66], and increased levels of OTR might also contribute to such resistance development for EGFR-targeted treatment in breast cancer patients. This evidence concerns the gene EGFR and breast carcinoma.